Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 249
Filter
Add more filters

Country/Region as subject
Publication year range
1.
Exp Dermatol ; 33(3): e15040, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38429888

ABSTRACT

The effect of persistent skin inflammation on extracutaneous organs and blood is not well studied. Patients with recessive dystrophic epidermolysis bullosa (RDEB), a severe form of the inherited blistering skin disorder, have widespread and persistent skin ulcers, and they develop various complications including anaemia, hyperglobulinaemia, hypoalbuminaemia and secondary amyloidosis. These complications are associated with the bioactivities of IL-6, and the development of secondary amyloidosis requires the persistent elevation of serum amyloid A (SAA) level. We found that patients with RDEB had significantly higher serum levels of IL-6 and SAA compared to healthy volunteers and patients with psoriasis or atopic dermatitis. Both IL-6 and SAA were highly expressed in epidermal keratinocytes and dermal fibroblasts of the skin ulcer lesions. Keratinocytes and fibroblasts surrounding the ulcer lesions are continuously exposed to Toll-like receptor (TLR) ligands, pathogen-associated and damage-associated molecular pattern molecules. In vitro, TLR ligands induced IL-6 expression via NF-κB in normal human epidermal keratinocytes (NHEKs) and dermal fibroblasts (NHDFs). SAA further induced the expression of IL-6 via TLR1/2 and NF-κB in NHEKs and NHDFs. The limitation of this study is that NHEKs and NHDFs were not derived from RDEB patients. These observations suggest that TLR-mediated persistent skin inflammation might increase the risk of IL-6-related systemic complications, including RDEB.


Subject(s)
Amyloidosis , Epidermolysis Bullosa Dystrophica , Interleukin-6 , Humans , Amyloidosis/metabolism , Amyloidosis/pathology , Collagen Type VII/metabolism , Epidermolysis Bullosa Dystrophica/metabolism , Epidermolysis Bullosa Dystrophica/pathology , Fibroblasts/metabolism , Inflammation/metabolism , Interleukin-6/metabolism , Keratinocytes/metabolism , NF-kappa B/metabolism , Serum Amyloid A Protein/metabolism , Toll-Like Receptors/metabolism
2.
Immunity ; 37(1): 74-84, 2012 Jul 27.
Article in English | MEDLINE | ID: mdl-22727489

ABSTRACT

Epithelial keratinocyte proliferation is an essential element of wound repair, and abnormal epithelial proliferation is an intrinsic element in the skin disorder psoriasis. The factors that trigger epithelial proliferation in these inflammatory processes are incompletely understood. Here we have shown that regenerating islet-derived protein 3-alpha (REG3A) is highly expressed in keratinocytes during psoriasis and wound repair and in imiquimod-induced psoriatic skin lesions. The expression of REG3A by keratinocytes is induced by interleukin-17 (IL-17) via activation of keratinocyte-encoded IL-17 receptor A (IL-17RA) and feeds back on keratinocytes to inhibit terminal differentiation and increase cell proliferation by binding to exostosin-like 3 (EXTL3) followed by activation of phosphatidylinositol 3 kinase (PI3K) and the kinase AKT. These findings reveal that REG3A, a secreted intestinal antimicrobial protein, can promote skin keratinocyte proliferation and can be induced by IL-17. This observation suggests that REG3A may mediate the epidermal hyperproliferation observed in normal wound repair and in psoriasis.


Subject(s)
Antigens, Neoplasm/metabolism , Biomarkers, Tumor/metabolism , Cell Differentiation , Keratinocytes/cytology , Keratinocytes/metabolism , Lectins, C-Type/metabolism , Skin/injuries , Skin/metabolism , Animals , Antigens, Neoplasm/genetics , Biomarkers, Tumor/genetics , Cell Differentiation/genetics , Cell Proliferation , Epidermis/drug effects , Epidermis/injuries , Epidermis/metabolism , Gene Expression/drug effects , Humans , Interleukin-17/pharmacology , Keratinocytes/drug effects , Lectins, C-Type/genetics , Mice , Mice, Inbred BALB C , Mice, Knockout , N-Acetylglucosaminyltransferases/metabolism , Pancreatitis-Associated Proteins , Phosphatidylinositol 3-Kinases/metabolism , Proteins/genetics , Proteins/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Psoriasis/immunology , Psoriasis/metabolism , Psoriasis/pathology , Signal Transduction , Skin/drug effects , Wound Healing/genetics
3.
Int J Mol Sci ; 22(20)2021 Oct 19.
Article in English | MEDLINE | ID: mdl-34681913

ABSTRACT

Histone deacetylase inhibitors (HDACis) are one of the therapeutic options for cutaneous T-cell lymphoma (CTCL), but they have limited effects. We previously demonstrated that HSP72 overexpression is associated with chemoresistance to HDACis in lymphoma cells. The purpose of this study was to investigate whether the functional depletion of HSP72 enhances the effect of the HDACi vorinostat. First, we established a stable HSP72-knockdown CTCL cell line and confirmed the influence of HSP72 reduction on the antitumor effects of vorinostat. Next, we studied the effect of quercetin, an inhibitor of HSP72, on the antineoplastic effects of vorinostat. In five CTCL cell lines examined, HSP72 expression was highest in Hut78 cells, and HSP72 knockdown enhanced vorinostat-induced apoptosis in these cells. Low-dose quercetin reduced HSP72 expression, increased HDAC activity, and enhanced vorinostat-induced suppression of Hut78 cell proliferation. A single low dose of quercetin induced G2 arrest and only slightly increased the sub-G1 cell fraction. Quercetin also significantly enhanced vorinostat-induced apoptosis, caspase-3, caspase-8, and caspase-9 activity, and the loss of mitochondrial membrane potential. HSP72 knockdown enhanced vorinostat-induced apoptosis in an HSP72-overexpressing CTCL cell line, and thus, quercetin may be a suitable candidate for combination therapy with vorinostat in clinical settings.


Subject(s)
HSP72 Heat-Shock Proteins/genetics , Lymphoma, T-Cell, Cutaneous/genetics , Quercetin/pharmacology , RNA, Small Interfering/pharmacology , Skin Neoplasms/genetics , Vorinostat/pharmacology , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/drug effects , Drug Resistance, Neoplasm/drug effects , Drug Synergism , Gene Expression Regulation, Neoplastic/drug effects , Gene Knockdown Techniques , HSP72 Heat-Shock Proteins/antagonists & inhibitors , Histone Deacetylases/metabolism , Humans , Lymphoma, T-Cell, Cutaneous/drug therapy , Skin Neoplasms/drug therapy
4.
J Med Virol ; 92(12): 3689-3696, 2020 Dec.
Article in English | MEDLINE | ID: mdl-32255500

ABSTRACT

Epstein-Barr virus (EBV) DNA load in the blood increases in posttransplant lymphoproliferative disorders and chronic active EBV infection. In this report, we analyzed the EBV DNA load in the peripheral blood mononuclear cells (PBMCs) and plasma of patients with hydroa vacciniforme (HV) and/or hypersensitivity to mosquito bites (HMB) to understand the clinical significance of EBV DNA load. All 30 patients showed high DNA loads in the PBMCs over the cut-off level. Of 16 plasma samples, extremely high in two samples obtained from patients with hemophagocytic lymphohistiocytosis (HLH). The amount of cell-free DNA in plasma was correlated to the serum levels of lactate dehydrogenase and inversely correlated to platelet counts. These results indicate that the EBV DNA load in PBMCs can provide one of the diagnostic indicators for HV and HMB and marked elevation of cell-free EBV DNA in plasma might be related to cytolysis such as that observed in HLH.

5.
J Infect Dis ; 220(8): 1307-1311, 2019 09 13.
Article in English | MEDLINE | ID: mdl-31240305

ABSTRACT

To evaluate diagnostic values for Epstein-Barr virus (EBV) DNA loads in different blood components of patients with EBV-positive T-cell/natural killer cell lymphoproliferative diseases, EBV DNA loads were compared among disease categories in each blood component from 59 patients. Plasma viral loads were significantly higher in "active" disease in chronic active EBV infection. EBV DNA was not detected in the plasma from 7 patients in whom EBV DNA was detected in peripheral blood mononuclear cells and whole blood. Diagnostic cutoff values for whole blood EBV DNA loads of patients with chronic active EBV infection compared with those of infectious mononucleosis was 104.2 (15 800) IU/mL.


Subject(s)
DNA, Viral/isolation & purification , Epstein-Barr Virus Infections/diagnosis , Herpesvirus 4, Human/isolation & purification , Infectious Mononucleosis/diagnosis , Lymphoproliferative Disorders/diagnosis , Diagnosis, Differential , Epstein-Barr Virus Infections/blood , Epstein-Barr Virus Infections/virology , Herpesvirus 4, Human/genetics , Humans , Infectious Mononucleosis/blood , Infectious Mononucleosis/virology , Lymphoproliferative Disorders/blood , Lymphoproliferative Disorders/virology , Prospective Studies , Reference Values , Viral Load
6.
J Am Acad Dermatol ; 81(5): 1086-1092.e1, 2019 Nov.
Article in English | MEDLINE | ID: mdl-30268591

ABSTRACT

BACKGROUND: Autosomal recessive congenital ichthyosis (ARCI) and ichthyosis syndrome (IS) are rare genetic skin disorders. OBJECTIVE: To estimate the number of patients with ARCI and IS in Japan and clarify the clinicoepidemiologic features of these diseases. METHODS: We performed a nationwide survey of patients treated for ARCI or IS during January 2005-December 2009. We developed diagnostic criteria and conducted a primary survey in a stratified random sample of Japanese hospitals to quantify the number of outpatients and inpatients with ARCI or IS. We performed a secondary survey of clinicoepidemiologic features in positive cases. RESULTS: The estimated number of patients receiving treatment for ARCI and IS during 2005-2009 was 220 (95% confidence interval [CI] 180-260). The estimated disease distribution was as follows: 95 (95% CI 80-110) patients with nonbullous congenital ichthyosiform erythroderma, 30 (95% CI 20-40) with lamellar ichthyosis, 15 (95% CI 10-20) with harlequin ichthyosis, and 85 (95% CI 50-120) with IS. LIMITATIONS: Patients with a mild case of the disease might not have visited a dermatology department, potentially causing underestimation of affected patients. CONCLUSION: We report the estimated number of patients with ARCI and IS in Japan and sex differences in the age distribution.


Subject(s)
Ichthyosiform Erythroderma, Congenital/epidemiology , Ichthyosis/epidemiology , Adolescent , Adult , Child , Cross-Sectional Studies , Epidemiologic Studies , Female , Genes, Recessive , Humans , Ichthyosiform Erythroderma, Congenital/diagnosis , Ichthyosiform Erythroderma, Congenital/genetics , Ichthyosis/diagnosis , Ichthyosis/genetics , Japan/epidemiology , Male , Middle Aged , Syndrome , Young Adult
7.
Hum Mol Genet ; 25(2): 328-39, 2016 Jan 15.
Article in English | MEDLINE | ID: mdl-26604146

ABSTRACT

In skin, basal keratinocytes in the epidermis are tightly attached to the underlying dermis by the basement membrane (BM). The correct expression of hemidesmosomal and extracellular matrix (ECM) proteins is essential for BM formation, and the null-expression of one molecule may induce blistering diseases associated with immature BM formation in humans. However, little is known about the significance of post-translational processing of hemidesmosomal or ECM proteins in BM formation. Here we show that the C-terminal cleavage of hemidesmosomal transmembrane collagen XVII (COL17) is essential for correct BM formation. The homozygous p.R1303Q mutation in COL17 induces BM duplication and blistering in humans. Although laminin 332, a major ECM protein, interacts with COL17 around p.R1303, the mutation leaves the binding of both molecules unchanged. Instead, the mutation hampers the physiological C-terminal cleavage of COL17 in the ECM. Consequently, non-cleaved COL17 ectodomain remnants induce the aberrant deposition of laminin 332 in the ECM, which is thought to be the major pathogenesis of the BM duplication that results from this mutation. As an example of impaired cleavage of COL17, this study shows that regulated processing of hemidesmosomal proteins is essential for correct BM organization in skin.


Subject(s)
Autoantigens/genetics , Autoantigens/metabolism , Basement Membrane/metabolism , Blister/metabolism , Cell Adhesion Molecules/metabolism , Non-Fibrillar Collagens/genetics , Non-Fibrillar Collagens/metabolism , Protein Processing, Post-Translational , Adult , Blister/genetics , Child , Epidermis/metabolism , Female , Humans , Japan , Keratinocytes/metabolism , Middle Aged , Mutation , Pedigree , Kalinin , Collagen Type XVII
8.
Exp Dermatol ; 27(2): 129-134, 2018 02.
Article in English | MEDLINE | ID: mdl-29087009

ABSTRACT

Double-stranded RNA (dsRNA) sensors including TLR3, MDA5 and RIG-I are expressed in epidermal keratinocytes and play an important immunological role by enhancing various innate and adaptive immune responses. Although the role of elevated extracellular calcium concentration in keratinocyte differentiation is well understood, the effect of high calcium on dsRNA sensors is not well studied. We investigated alterations in dsRNA sensor expression and antiviral activity induced by a high extracellular concentration of calcium in epidermal keratinocytes. Normal human epidermal keratinocytes (NHEKs) were stimulated with high calcium and/or synthetic dsRNA, poly (I:C). TLR3, IFIH1 (MDA5) and DDX58 (RIG-I) expression were measured via qPCR, and IFN-ß and human beta-defensin 2 (HBD2) levels were measured using ELISA. TLR3 localization was evaluated with immunocytofluorescence. Antiviral activity was quantified with virus plaque assays using herpes simplex virus type 1 (HSV-1). High calcium significantly upregulated mRNA expression of TLR3, IFIH1 and DDX58 in NHEKs. In addition, high calcium significantly enhanced poly (I:C)-induced anti-HSV-1 activity in NHEKs. The antiviral molecule HBD2 but not IFN-ß induction by poly (I:C) was enhanced by high calcium. Our findings indicate that high levels of extracellular calcium enhance the expression of dsRNA sensors and augment antiviral activity in epidermal keratinocytes.


Subject(s)
Calcium/metabolism , Keratinocytes/cytology , Keratinocytes/immunology , RNA, Double-Stranded/metabolism , DEAD Box Protein 58/metabolism , Epidermis/metabolism , Herpesvirus 1, Human , Humans , Immunity, Innate , Interferon-Induced Helicase, IFIH1/metabolism , Poly I-C/pharmacology , Receptors, Immunologic , Signal Transduction , Skin/pathology , Toll-Like Receptor 3/metabolism , Up-Regulation , Viral Plaque Assay , beta-Defensins/metabolism
9.
Acta Med Okayama ; 72(2): 185-187, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29674768

ABSTRACT

Psoriasis is a common chronic inflammatory skin disorder that is characterized by scaly, erythematous, sharply demarcated plaques. The treatment for psoriasis has dramatically changed over the last 10 years with the introduction of biologics. However, the risk of cancer induced by biologics for psoriasis has not been fully analyzed, since these agents have such a short history of use. Here we report the case of a 74-year-old woman with psoriasis vulgaris and psoriatic arthritis complicated by breast cancer after systemic treatments including etretinate, cyclosporine, methotrexate, adalimumab, and ustekinumab.


Subject(s)
Biological Products/therapeutic use , Breast Neoplasms/complications , Psoriasis/complications , Psoriasis/drug therapy , Aged , Anastrozole , Antineoplastic Agents, Hormonal/therapeutic use , Breast Neoplasms/drug therapy , Female , Humans , Immunosuppressive Agents/therapeutic use , Nitriles/therapeutic use , Triazoles/therapeutic use
10.
Acta Med Okayama ; 72(3): 275-282, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29926005

ABSTRACT

Lympho-epithelial Kazal-type-related inhibitor (LEKTI) is a large multidomain serine protease inhibitor that is expressed in epidermal keratinocytes. Nonsense mutations of the SPINK5 gene, which codes for LEKTI, cause Netherton syndrome, which is characterized by hair abnormality, ichthyosis, and atopy. A single nucleotide polymorphism (SNP) of SPINK5, p.K420E, is reported to be associated with the pathogenesis of atopic dermatitis (AD). We studied all 34 exons of the SPINK5 gene in Japanese 57 AD patients and 50 normal healthy controls. We detected nine nonsynonymous variants, including p.K420E; these variants had already been registered in the SNP database. Among them, p.R654H (n=1) was found as a heterozygous mutation in the AD patients, but not in the control. No new mutation was detected. We next compared the data of the AD patients with data from the Human Genetic Variation Database provided by Kyoto University; a significant difference was found in the frequency of the p.S368N genotype distribution. PolyPhen-2 and SIFT, two algorithms for predicting the functional effects of amino acid substitutions, showed significant scores for p.R654H. Therefore, R654H might be a risk factor for epidermal barrier dysfunction in some Japanese AD patients.


Subject(s)
Dermatitis, Atopic/genetics , Exons , Mutation , Polymorphism, Single Nucleotide , Serine Peptidase Inhibitor Kazal-Type 5/genetics , Adult , Genotype , Humans , Middle Aged
11.
Cancer Sci ; 108(5): 1022-1031, 2017 May.
Article in English | MEDLINE | ID: mdl-28266140

ABSTRACT

Promising antitumor activities of nivolumab, a fully humanized IgG4 inhibitor antibody against the programmed death-1 protein, were suggested in previous phase 1 studies. The present phase 2, single-arm study (JAPIC-CTI #111681) evaluated the antitumor activities of nivolumab and explored its predictive correlates in advanced melanoma patients at 11 sites in Japan. Intravenous nivolumab 2 mg/kg was given repeatedly at 3-week intervals to 35 of 37 patients enrolled from December 2011 to May 2012 until they experienced unacceptable toxicity, disease progression, or complete response. Primary endpoint was objective response rate. Serum levels of immune modulators were assessed at multiple time points. As of 21 October 2014, median response duration, median progression-free survival, and median overall survival were 463 days, 169 days, and 18.0 months, respectively. The overall response rate and 1- and 2-year survival rates were 28.6%, 54.3%, and 42.9%, respectively. Thirteen patients remained alive at the end of the observation period and no deaths were drug related. Grade 3-4 drug-related adverse events were observed in 31.4% of patients. Pretreatment serum interferon-γ, and interleukin-6 and -10 levels were significantly higher in the patients with objective tumor responses than in those with tumor progression. In conclusion, giving repeated i.v. nivolumab had potent and durable antitumor effects and a manageable safety profile in advanced melanoma patients, strongly suggesting the usefulness of nivolumab for advanced melanoma and the usefulness of pretreatment serum cytokine profiles as correlates for predicting treatment efficacy.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/therapeutic use , Biomarkers/metabolism , Cytokines/metabolism , Melanoma/drug therapy , Melanoma/metabolism , Aged , Disease Progression , Disease-Free Survival , Female , Humans , Interferon-gamma/metabolism , Interleukin-10/metabolism , Interleukin-6/metabolism , Male , Melanoma/pathology , Nivolumab , Survival Rate
12.
Exp Dermatol ; 26(11): 1026-1032, 2017 11.
Article in English | MEDLINE | ID: mdl-28418601

ABSTRACT

Human ß-defensin-3 (HBD-3) possesses antimicrobial activities and the potential to induce proinflammatory cytokines. HBD-3 contains a unique motif of two arginine residues (Arg or R) in the COOH-terminal region. To understand the bioactive properties of the Arg residues of HBD-3, we examined antimicrobial activities against Staphylococcus aureus and Pseudomonas aeruginosa using synthetic HBD-2, HBD-3 and two variant peptides of HBD-3: the Arg-truncated variant designated desR HBD-3 and NRR HBD-3, in which both Arg residues were shifted to the N-terminal region. IL-6 production from keratinocytes was studied using the peptides. HBD-3 possessed approximately five-fold more potent antimicrobial activities, evaluated as the minimum inhibitory concentration (MIC), against S. aureus compared with desR and NRR HBD-3, while no significant activity was observed in HBD-2. The antimicrobial activity of HBD-3 against S. aureus was well preserved even at high sodium chloride concentrations, but was attenuated in desR and NRR HBD-3. All the peptides exhibited similar antimicrobial activities against P. aeruginosa, but HBD-2 and desR HBD-3 showed diminished antimicrobial activities against P. aeruginosa at high salt concentrations. IL-6 production was significantly induced in keratinocytes with HBD-3, but not remarkably with stimulation by other peptide. These Arg residues are essential for the antimicrobial and biological properties of HBD-3.


Subject(s)
Interleukin-6/genetics , Pseudomonas aeruginosa/drug effects , Staphylococcus aureus/drug effects , beta-Defensins/chemistry , beta-Defensins/pharmacology , Arginine/chemistry , Cells, Cultured , Gene Expression , Humans , Interleukin-6/biosynthesis , Keratinocytes/drug effects , Keratinocytes/metabolism , Microbial Sensitivity Tests , Pseudomonas aeruginosa/genetics , Recombinant Proteins/pharmacology , Sodium Chloride/pharmacology , Staphylococcus aureus/genetics
13.
J Infect Chemother ; 23(8): 503-511, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28645883

ABSTRACT

To investigate the trends of antimicrobial resistance in pathogens isolated from skin and soft-tissue infections (SSTI) at dermatology departments in Japan, a Japanese surveillance committee conducted the first nationwide survey in 2013. Three main organisms were collected from SSTI at 30 dermatology departments in medical centers and 10 dermatology clinics. A total of 860 strains - 579 of Staphylococcus aureus, 240 of coagulase-negative Staphylococci, and 41 of Streptococcus pyogenes - were collected and shipped to a central laboratory for antimicrobial susceptibility testing. The patient profiles were also studied. Among all 579 strains of S. aureus, 141 (24.4%) were methicillin-resistant (MRSA). Among 97 Staphylococcus epidermidis strains, 54 (55.7%) were methicillin-resistant (MRSE). MRSA and MRSE were more frequently isolated from inpatients than from outpatients. Furthermore, these methicillin-resistant strains were also isolated more frequently from patients with histories of taking antibiotics within 4 weeks and hospitalization within 1 year compared to those without. However, there were no significant differences in MIC values and susceptibility patterns of the MRSA strains between patients with a history of hospitalization within 1 year and those without. Therefore, most of the isolated MRSA cases at dermatology departments are not healthcare-acquired, but community-acquired MRSA. S. pyogenes strains were susceptible to most antibiotics except macrolides. The information in this study is not only important in terms of local public health but will also contribute to an understanding of epidemic clones of pathogens from SSTI.


Subject(s)
Anti-Bacterial Agents/pharmacology , Drug Resistance, Bacterial , Soft Tissue Infections/microbiology , Staphylococcal Skin Infections/microbiology , Staphylococcus aureus/drug effects , Streptococcal Infections/microbiology , Streptococcus pyogenes/drug effects , Cross-Sectional Studies , Dermatology , Hospitalization/statistics & numerical data , Humans , Japan/epidemiology , Methicillin-Resistant Staphylococcus aureus/drug effects , Microbial Sensitivity Tests , Soft Tissue Infections/epidemiology , Staphylococcal Skin Infections/epidemiology , Streptococcal Infections/epidemiology
14.
Appl Environ Microbiol ; 82(23): 6930-6941, 2016 Dec 01.
Article in English | MEDLINE | ID: mdl-27663023

ABSTRACT

Ethidium monoazide and propidium monoazide (EMA and PMA) have been used in combination with PCR for more than a decade to facilitate the discrimination of live and dead bacteria (LD discrimination). These methods, however, require many laborious procedures, including the use of a darkroom. Here, we demonstrate an innovative use of palladium compounds involving lower limits of detection and quantification of targeted live cells, fewer laborious procedures, lower costs, and potentially higher-throughput analysis than the use of EMA and PMA. We have also recently reported platinum compounds for LD discrimination, but platinum compounds carry costs that are 3 times higher because of the requirement for much larger amounts for LD discrimination than palladium compounds. Palladium compounds can penetrate dead (compromised) but not live bacteria and can be chelated primarily by chromosomal DNA and cell wall transmembrane proteins, with small amounts of DNA-binding proteins in vivo The new mechanism for palladium compounds is obviously different from that of platinum compounds, which primarily target DNA. Combining palladium compounds with PCR (Pd-PCR) in water resulted in discrimination between live and dead Enterobacteriaceae bacteria that was much clearer than that seen with the PMA method. Pd-PCR correlated with reference plating or with the currently used PMA-PCR method for pasteurized milk, based on EN ISO 16140:2003 validation. Pd-PCR enabled us to specifically detect and assay viable Enterobacteriaceae cells at concentrations of 5 to 10 CFU/ml in milk while following U.S./EU regulations after a 4.5-h process in a typical laboratory exposed to natural or electric light, as specified by U.S./EU regulations.IMPORTANCE Ethidium monoazide and propidium monoazide (EMA and PMA) facilitate the discrimination of live and dead bacteria (LD discrimination). These methods, however, require many laborious procedures, including the use of a darkroom. Here, we demonstrate an innovative use of palladium compounds involving fewer laborious procedures, lower costs, and potentially higher-throughput analysis than the use of EMA and PMA. We have also recently reported platinum compounds for LD discrimination, but platinum compounds carry costs that are 3 times higher because of the requirement for much larger amounts for LD discrimination than palladium compounds, which have also a novel reaction mechanism different from that of platinum compounds. In view of testing cost, palladium compounds are also very useful here compared with platinum compounds. Ultimately, the innovative Pd-PCR method may be also substituted for the currently used reference plating methods.

15.
J Biol Chem ; 289(34): 23389-402, 2014 Aug 22.
Article in English | MEDLINE | ID: mdl-25002577

ABSTRACT

The receptor for advanced glycation end products (RAGE) is involved in the pathogenesis of many inflammatory, degenerative, and hyperproliferative diseases, including cancer. Previously, we revealed mechanisms of downstream signaling from ligand-activated RAGE, which recruits TIRAP/MyD88. Here, we showed that DNAX-activating protein 10 (DAP10), a transmembrane adaptor protein, also binds to RAGE. By artificial oligomerization of RAGE alone or RAGE-DAP10, we found that RAGE-DAP10 heterodimer formation resulted in a marked enhancement of Akt activation, whereas homomultimeric interaction of RAGE led to activation of caspase 8. Normal human epidermal keratinocytes exposed to S100A8/A9, a ligand for RAGE, at a nanomolar concentration mimicked the pro-survival response of RAGE-DAP10 interaction, although at a micromolar concentration, the cells mimicked the pro-apoptotic response of RAGE-RAGE. In transformed epithelial cell lines, A431 and HaCaT, in which endogenous DAP10 was overexpressed, and S100A8/A9, even at a micromolar concentration, led to cell growth and survival due to RAGE-DAP10 interaction. Functional blocking of DAP10 in the cell lines abrogated the Akt phosphorylation from S100A8/A9-activated RAGE, eventually leading to an increase in apoptosis. Finally, S100A8/A9, RAGE, and DAP10 were overexpressed in the psoriatic epidermis. Our findings indicate that the functional interaction between RAGE and DAP10 coordinately regulates S100A8/A9-mediated survival and/or apoptotic response of keratinocytes.


Subject(s)
Keratinocytes/metabolism , Receptors, Immunologic/metabolism , Signal Transduction , Calgranulin A/metabolism , Calgranulin B/metabolism , Cells, Cultured , Humans , Killer Cells, Natural/immunology , Psoriasis/metabolism , RNA Interference , Receptor for Advanced Glycation End Products
16.
Acta Med Okayama ; 69(1): 17-27, 2015.
Article in English | MEDLINE | ID: mdl-25703167

ABSTRACT

Sentinel lymph node (SLN) biopsies have widely been used for the detection of occult LN metastasis of malignant melanoma (MM). In addition to conventional biomarkers, we assessed the diagnostic and prognostic significance of melanoma-initiating cell (MIC) markers in SLNs of MM. We examined the expressions of gp100, MART-1 and tyrosinase mRNA for routine diagnosis and those of ABCB5, CD133, nestin, KDM5B, NGFR and RANK mRNA as MIC markers. The presence of micrometastasis was confirmed immunohistochemically using antibodies to S-100, HMB-45, MART-1, and tyrosinase. Discordance between immunohistochemical and molecular data was observed in 14 of 70 (20.0%) patients, among whom five (7.1%) were positive for only molecular markers;two of these five patients tested positive for micrometastasis by repeated immunohistochemical stainings. The quantitative expression levels of gp100, MART-1, and tyrosinase mRNA were significantly higher in the metastatic LNs;the cut-off values remain to be elucidated. ABCB5 mRNA expression was detected more frequently in the metastatic SLNs (p<0.05) and in the group of patients with recurrence. To make a definite diagnosis of metastasis, we still need a combination of immunohistochemical and molecular probes. ABCB5 might be a suitable molecular marker for the detection of melanoma-initiating cells in SLNs.


Subject(s)
Melanoma/pathology , Neoplastic Stem Cells/metabolism , Sentinel Lymph Node Biopsy , ATP Binding Cassette Transporter, Subfamily B , ATP Binding Cassette Transporter, Subfamily B, Member 1/analysis , ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , Aged , Aged, 80 and over , Biomarkers , Female , Humans , Immunohistochemistry , Jumonji Domain-Containing Histone Demethylases/analysis , Jumonji Domain-Containing Histone Demethylases/genetics , MART-1 Antigen/genetics , Male , Middle Aged , Nuclear Proteins/analysis , Nuclear Proteins/genetics , RNA, Messenger/analysis , Repressor Proteins/analysis , Repressor Proteins/genetics
17.
Br J Nutr ; 111(10): 1801-10, 2014 May 28.
Article in English | MEDLINE | ID: mdl-24472388

ABSTRACT

Accumulating evidence suggests that orally ingested lactoferrin protects against inflammation. To assess the efficacy of orally administered bovine lactoferrin (bLF) against hepatitis and to identify the underlying mechanism, in the present study, we used four mouse models of hepatitis induced by d-galactosamine (GalN), carbon tetrachloride (CCl4), GalN plus lipopolysaccharide (LPS) and zymosan plus LPS. Intraperitoneal (i.p.) injection of GalN (500 mg/kg body weight) in mice treated with bovine serum albumin (BSA) for 14 d significantly increased serum aspartate aminotransferase (AST) concentrations compared with the untreated mice. However, orally administered bLF reduced AST concentrations compared with BSA treatment. In mice that received a single injection (0·4 ml/kg) and twice-weekly injections (0·08 ml/kg) of CCl4 for 24 weeks and pretreated with bLF for 14 d and 24 weeks, respectively, significantly suppressed alanine aminotransferase and AST concentrations were observed compared with the BSA-treated control. Oral administration of bLF for 14 d before i.p. injection of LPS (5 mg/kg) plus GalN (1 g/kg) significantly improved the survival rate. In mice that received intravenous injection of zymosan (25 mg/kg) and LPS (15 µg/kg) at 7 d intervals, bLF reduced the elevation of AST concentrations and enhanced the production of IL-11 and bone morphogenetic protein 2 in the small intestine compared with the BSA-treated control. To evaluate the effects of IL-11, we used IL-11 receptor α-null mice treated with GalN, CCl4 and zymosan plus LPS. In this group, the activity of bLF was not significantly different from that of BSA. These data indicate that orally ingested bLF enhances the expression of IL-11 in the small intestine and up-regulates protective activity in mice with hepatitis.


Subject(s)
Alanine Transaminase/blood , Hepatitis/metabolism , Interleukin-11/metabolism , Intestine, Small/metabolism , Lactoferrin/administration & dosage , Serum Albumin, Bovine/administration & dosage , Administration, Intravenous , Administration, Oral , Analysis of Variance , Animals , Bone Morphogenetic Protein 2/metabolism , Cattle , Disease Models, Animal , Hepatitis/pathology , Intestine, Small/cytology , Intestine, Small/drug effects , Lactoferrin/metabolism , Liver/metabolism , Liver/pathology , Mice , Mice, Inbred Strains , RNA, Messenger , Serum Albumin, Bovine/metabolism , Tumor Necrosis Factor-alpha/metabolism , Up-Regulation
18.
Int J Hematol ; 2024 May 03.
Article in English | MEDLINE | ID: mdl-38700651

ABSTRACT

When Epstein-Barr virus (EBV) infection is suspected, identification of infected cells is important to understand the pathogenesis, determinine the treatment strategy, and predict the prognosis. We used the PrimeFlow™ RNA Assay Kit with a probe to detect EBV-encoded small RNAs (EBERs) and multiple surface markers, to identify EBV-infected cells by flow cytometry. We analyzed a total of 24 patients [11 with chronic active EBV disease (CAEBV), 3 with hydroa vacciniforme lymphoproliferative disorder, 2 with X-linked lymphoproliferative disease type 1 (XLP1), 2 with EBV-associated hemophagocytic lymphohistiocytosis, and 6 with posttransplant lymphoproliferative disorder (PTLD)]. We compared infected cells using conventional quantitative PCR methods and confirmed that infected cell types were identical in most patients. Patients with CAEBV had widespread infection in T and NK cells, but a small amount of B cells were also infected, and infection in patients with XLP1 and PTLD was not limited to B cells. EBV-associated diseases are believed to be complex pathologies caused by EBV infecting a variety of cells other than B cells. We also demonstrated that infected cells were positive for HLA-DR in patients with CAEBV. EBER flow FISH can identify EBV-infected cells with high sensitivity and is useful for elucidating the pathogenesis.

19.
Biochim Biophys Acta ; 1820(12): 1980-6, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22982588

ABSTRACT

BACKGROUND: Live and injured bacteria cannot be successfully discriminated using flow cytometric methods (FCM) with commercial live/dead staining agents because injured cells have intact cell membranes and are counted as live cells. We previously reported that photoactivated ethidium monoazide (EMA) directly cleaves bacterial DNA both in vivo and in vitro (Microbiol. Immunol. 51:763-775, 2007). METHODS: We report that EMA cleaves the chromosomal DNA of antibiotic-injured, but not live, Listeria monocytogenes. The combination of FCM and EMA treatment was evaluated as a rapid method to discriminate between live and antibiotic-injured L. monocytogenes. Additionally, we evaluated our methodology using blood from pediatric patients infected with other gram-negative and gram-positive bacteria. RESULTS: For antibiotic-injured, but not live, L. monocytogenes in blood, photoactivated EMA suppressed SYTO9 staining, as the SYTO9 staining of the antibiotic-injured L. monocytogenes was weak compared with that of live cells. Similarly, the rapid and clear discrimination between live and injured bacteria (gram-negative and gram-positive) was performed using the blood of pediatric patients administered antibiotics. CONCLUSIONS: The combination of FCM with EMA treatment is a rapid method for evaluating the susceptibility of live pathogens in infants with bacteremia without the need for bacterial culture. GENERAL SIGNIFICANCE: This assay is more rapid than other currently available techniques due to the elimination of the time-consuming culture step and could be used in clinical settings to rapidly determine the success of antibiotic treatment in pediatric bacteremia through the discrimination of injured (i.e., susceptible to the administered antibiotics) and live pathogens.


Subject(s)
Anti-Bacterial Agents/pharmacology , Bacteremia/drug therapy , DNA, Bacterial/metabolism , Flow Cytometry/methods , Listeria monocytogenes/drug effects , Microbial Viability/drug effects , Affinity Labels/pharmacology , Azides/pharmacology , Bacteremia/metabolism , Bacteremia/microbiology , DNA, Bacterial/genetics , Erythrocytes/drug effects , Erythrocytes/metabolism , Erythrocytes/microbiology , Granulocytes/drug effects , Granulocytes/metabolism , Granulocytes/microbiology , Humans , Infant , Light , Listeria monocytogenes/growth & development , Lymphocytes/drug effects , Lymphocytes/metabolism , Lymphocytes/microbiology , Monocytes/drug effects , Monocytes/metabolism , Monocytes/microbiology , Photoaffinity Labels
20.
Appl Environ Microbiol ; 79(6): 1843-9, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23315725

ABSTRACT

Lactoferrin is an iron-binding glycoprotein found in the milk of most mammals for which various biological functions have been reported, such as antimicrobial activity and bifidogenic activity. In this study, we compared the bifidogenic activity of bovine lactoferrin (bLF) and pepsin hydrolysate of bLF (bLFH), isolated bifidogenic peptide from bLFH, and investigated the bifidogenic spectra of bLF, bLFH, and its active peptide against 42 bifidobacterial strains comprising nine species. Against Bifidobacterium breve ATCC 15700(T), minimal effective concentrations of bLF and bLFH were 300 and 10 µg/ml. Against Bifidobacterium longum subsp. infantis ATCC 15697(T), the minimal effective concentration of bLFH was 30 µg/ml, and bLF did not show bifidogenic activity within 300 µg/ml. As an active peptide, a heterodimer of A(1)-W(16) and L(43)-A(48) linked by a disulfide bond was isolated. Previously, this peptide was identified as having antibacterial activity. An amino acid mixture with the same composition as this peptide showed no bifidogenic activity. The strains of each species whose growth was highly promoted (>150%) by this peptide at 3.75 µM were as follows: B. breve (7 out of 7 strains [7/7]), B. longum subsp. infantis (5/5), Bifidobacterium bifidum (2/5), B. longum subsp. longum (1/3), Bifidobacterium adolescentis (3/6), Bifidobacterium catenulatum (1/4), Bifidobacterium pseudocatenulatum (0/4), Bifidobacterium dentium (0/5), and Bifidobacterium angulatum (0/3). Growth of none of the strains was highly promoted by bLF at 3.75 µM. We demonstrated that bLFH showed stronger bifidogenic activity than natural bLF, especially against infant-representative species, B. breve and B. longum subsp. infantis; furthermore, we isolated its active peptide. This is the first report about a bifidogenic peptide derived from bLF.


Subject(s)
Bifidobacterium/drug effects , Bifidobacterium/growth & development , Growth Inhibitors/isolation & purification , Intercellular Signaling Peptides and Proteins/isolation & purification , Lactoferrin/metabolism , Pepsin A/metabolism , Animals , Cattle , Growth Inhibitors/pharmacology , Hydrolysis , Intercellular Signaling Peptides and Proteins/pharmacology , Microbial Sensitivity Tests
SELECTION OF CITATIONS
SEARCH DETAIL